Altamira Therapeutics Ltd. (CYTO)

1.7800 +0.0700 (+4.09%) 收市：04:00PM EDT

Altamira Therapeutics Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
441 295 5950
https://altamiratherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 10

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Thomas Meyer Ph.D.	Founder, President, Chairman, CEO & MD	563.85k	無	1968
Mr. Marcel Gremaud CPA	Chief Financial Officer	無	無	1959
Dr. Covadonga Paneda	Chief Operating Officer	無	無	1974
Dr. Samuel A. Wickline M.D.	Chief Scientific Adviser	無	無	1953

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

公司管治

截至 無 止，Altamira Therapeutics Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。